Comparison of efficacy and safety of atorvastatin 5% lotion and betamethasone 0.1% lotion in the treatment of scalp seborrheic dermatitis

Figures & data

Figure 1 Clinical trial flowchart of the study.

Table 1 Comparison of baseline background and demographic variables between two groups

Variable	Atorvastatin group (n=45)	Betamethasone group (n=41)
Sex
Male, n (%) Female, n (%)	29 (64.5%) 16 (35.5%)	26 (63.4%) 15 (36.6%)
Age, years (mean ± Std. Dev.)	30.37±7.24	28.09±7.22
BMI, kg/m^2 (mean ± Std. Dev.)	23.28±3.2	24.39±3.3
Duration of disease, months (mean ± Std. Dev.)	18±8.2	21.6±4.5
SSSD score (mean ± Std. Dev.)	6.66±0.93	7.12±1.26

Abbreviations: BMI, Body Mass Index; SSSD, Symptom Scale of Seborrheic Dermatitis; Std.Dev., Standard Deviation.

Figure 2 Changes in SSSD score from baseline to week 4 by treatment group (histogram). The frequency in figure 2 is number of patients and the diffindex is changes in SSSD score from baseline to week 4.

Abbreviations: SSSD, Symptom Scale of Seborrheic Dermatitis.; Std. Dev., standard deviation.

Table 2 Mean changes in SSSD score from baseline (visit 1) to week 4 (visit 2) by treatment group

	Atorvastatin group (n=45)	Betamethasone group (n=45)	Difference, atorvastatin–betamethasone	P-value
Mean [two-sided 95% CI]	−6.35 [−6.04,−6.95]	−6.48 [−6.02,−6.69]	0.13 [−0.48,0.70]	0.65

Abbreviation: SSSD, Symptom Scale of Seborrheic Dermatitis.

Table 3 Summary of the effects of interventions in the severity of seborrheic dermatitis (mean ± Std. Dev.)

Variables	Groups		P-value
	Atorvastatin	Betamethasone
Baseline severity	6.66±0.92	7.12±1.26	0.06
Endpoint severity	0.31±0.56	0.63±1.04	0.08
P-value	<0.001	<0.001
Difference between endpoint and baseline severity	6.35±1.15	6.48±1.50	0.65

Table 4 Patients’ frequency distribution while considering after-treatment satisfaction on the 28th day of treatment

Group	Satisfaction frequency of treatment				Total	P-value
	Non	Mild	Moderate	Good
Betamethasone (n)	1 (2.4%)	9 (22.0%)	10 (24.4%)	21 (51.2%)	41	0.49
Atorvastatin (n)	1 (2.2%)	6 (13.3%)	8 (17.8%)	30 (66.7%)	45
Total (n)	2 (2.3%)	15 (17.4%)	18 (20.9%)	51 (59.3%)	86 (100%)